Emerging research suggest Retatrutide , a dual agonist targeting both incretin and glucose-dependent insulinotropic polypeptide , may provide a promising advancement for weight loss . Preliminary patient investigations have indicated considerable decreases in visceral fat , potentially outperforming existing weight-loss treatments. Despite this, mo